These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
114 related articles for article (PubMed ID: 30798740)
1. Response to "Systemic Bevacizumab for Hereditary Hemorrhagic Telangiectasia: Considerations from Observational Studies". Hsu YP; Hsu CW; Chen C Otolaryngol Head Neck Surg; 2019 Feb; 160(2):369-370. PubMed ID: 30798740 [No Abstract] [Full Text] [Related]
2. Systemic Bevacizumab for Hereditary Hemorrhagic Telangiectasia: Considerations from Observational Studies. Al-Samkari H Otolaryngol Head Neck Surg; 2019 Feb; 160(2):368. PubMed ID: 30798765 [No Abstract] [Full Text] [Related]
3. Bevacizumab as a treatment for hereditary hemorrhagic telangiectasia in children: a case report. Ospina FE; Echeverri A; Posso-Osorio I; Jaimes L; Gutierrez J; Tobón GJ Colomb Med (Cali); 2017 Jun; 48(2):88-93. PubMed ID: 29021642 [TBL] [Abstract][Full Text] [Related]
4. Intermittent low-dose bevacizumab in hereditary hemorrhagic telangiectasia : A case report. Huemer F; Dejaco M; Grabmer C; Melchardt T; Neureiter D; Mayer G; Egle A; Greil R; Weiss L Wien Klin Wochenschr; 2017 Feb; 129(3-4):141-144. PubMed ID: 27878613 [TBL] [Abstract][Full Text] [Related]
5. Successful therapy with bevacizumab in a case of hereditary hemorrhagic telangiectasia. Kochanowski J; Sobieszczańska M; Tubek S; Żurek M; Pawełczak J Hum Vaccin Immunother; 2015; 11(3):680-1. PubMed ID: 25839219 [TBL] [Abstract][Full Text] [Related]
6. Is bevacizumab effective for reducing epistaxis in hereditary hemorrhagic telangiectasia? Chin CJ Laryngoscope; 2017 Feb; 127(2):289-290. PubMed ID: 27796042 [No Abstract] [Full Text] [Related]
7. [Bevacizumab in therapy-refractory epistaxis: case report of low-dose antibody therapy for hereditary hemorrhagic telangiectasia]. Rohrmeier C; Kühnel TS HNO; 2012 Nov; 60(11):1003-6. PubMed ID: 22706563 [TBL] [Abstract][Full Text] [Related]
8. Pazopanib effective for bevacizumab-unresponsive epistaxis in hereditary hemorrhagic telangiectasia. Parambil JG; Woodard TD; Koc ON Laryngoscope; 2018 Oct; 128(10):2234-2236. PubMed ID: 29451965 [TBL] [Abstract][Full Text] [Related]
13. Osteonecrosis after intranasal injection with bevacizumab in treating hereditary hemorrhagic telangiectasia: A case report. Steineger J; Merckoll E; Slåstad JM; Eriksen EF; Heimdal K; Dheyauldeen S Laryngoscope; 2018 Mar; 128(3):593-596. PubMed ID: 28671294 [TBL] [Abstract][Full Text] [Related]
14. Bevacizumab in patients with hereditary hemorrhagic telangiectasia and severe hepatic vascular malformations and high cardiac output. Dupuis-Girod S; Ginon I; Saurin JC; Marion D; Guillot E; Decullier E; Roux A; Carette MF; Gilbert-Dussardier B; Hatron PY; Lacombe P; Lorcerie B; Rivière S; Corre R; Giraud S; Bailly S; Paintaud G; Ternant D; Valette PJ; Plauchu H; Faure F JAMA; 2012 Mar; 307(9):948-55. PubMed ID: 22396517 [TBL] [Abstract][Full Text] [Related]
15. Bevacizumab in hereditary hemorrhagic telangiectasia-associated epistaxis: effectiveness of an injection protocol based on the vascular anatomy of the nose. Dheyauldeen S; Østertun Geirdal A; Osnes T; Vartdal LS; Dollner R Laryngoscope; 2012 Jun; 122(6):1210-4. PubMed ID: 22565282 [TBL] [Abstract][Full Text] [Related]
16. Intravenous Bevacizumab in Hereditary Hemorrhagic Telangiectasia: A Role That Is Still to Be Defined. Dupuis-Girod S Mayo Clin Proc; 2020 Aug; 95(8):1565-1566. PubMed ID: 32753127 [No Abstract] [Full Text] [Related]
17. Intravenous bevacizumab for complications of hereditary hemorrhagic telangiectasia: a review of the literature. Arizmendez NP; Rudmik L; Poetker DM Int Forum Allergy Rhinol; 2015 Nov; 5(11):1042-7. PubMed ID: 26202958 [TBL] [Abstract][Full Text] [Related]